The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 17, 2018

Filed:

Nov. 01, 2013
Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Irene Ghobrial, Wellesley, MA (US);

Aldo M. Roccaro, Boston, MA (US);

Salomon Manier, Boston, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); A61K 39/395 (2006.01); C12N 15/113 (2010.01); A61K 35/14 (2015.01); A61K 45/06 (2006.01); A61K 31/436 (2006.01); A61K 31/69 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/436 (2013.01); A61K 31/69 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 35/14 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2887 (2013.01); C12N 15/113 (2013.01); A61K 2039/505 (2013.01); C12N 2310/141 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/178 (2013.01);
Abstract

This invention is based, at least in part, on the finding that certain microRNAs (miRNAs) are expressed at higher or lower levels in circulating exosonies or peripheral blood of subjects with hematological malignancies compared to the level of expression in subjects who do not have the hematological malignancy. In addition, this invention is based, at least in part, on the finding that certain miRNAs are differentially expressed at different stages of a hematological malignancy permitting identification of the stage of the hematological malignancy in a subject. The differential expression of miRNAs at different stages of a hematological malignancy also permits determination of the effectiveness of treatments administered to a subject at the particular stage of the hematological malignancy.


Find Patent Forward Citations

Loading…